<DOC>
	<DOC>NCT01597895</DOC>
	<brief_summary>The purpose of this study is to determine the effect that telaprevir and boceprevir has on the pharmacokinetics of maraviroc.</brief_summary>
	<brief_title>Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Healthy male and/or female subjects. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2. Total body weight &gt;50 kg (110 lbs). Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 halflives (whichever is longer) prior to the first dose of study medication. Use of tobacco or nicotinecontaining products in excess of the equivalent of 5 cigarettes per day. Positive result for HIV1, HIV2, Hepatitis B serology (HbsAg, HbcAb) or anti hepatitis C virus serology (as determined by a multi antigen EIA).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>maraviroc</keyword>
	<keyword>boceprevir</keyword>
	<keyword>telaprevir</keyword>
	<keyword>drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>HIV</keyword>
</DOC>